【症例報告】スギ花粉症に対するオマリズマブの使用経験─適応症例について考える─

笹沼 里圭子, 増山 敬祐
2021
Omalizumab, a recombinant humanized monoclonal anti-IgE antibody can bind to the serum free IgE molecule thus block the interaction between IgE and mast cells, which triggers allergic responses. Omalizumab therapy has been approved in Japan for the treatment of allergic asthma and idiopathic chronic urticaria. In addition, treatment of Japanese cedar pollinosis with omalizumab was approved in December 2019, and it is now feasible to use omalizumab for treating Japanese cedar pollen-induced
more » ... nal allergic rhinitis. We treated three cases of severe Japanese cedar pollinosis with omalizumab during the 2020 pollen season and here report the effi cacy of this therapy.
doi:10.34429/00005054 fatcat:2lx7okrfdzh5rel3clodwfbqsu